Arbutus Biopharma (ABUS) closed at $4.03 on November 12, 2026, up 3.9% from the previous close, on volume of 3,700,824 shares (30-day average 3,476,283).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 11, 2026 | Calendar Put Spread | 15-Jan : 17-Jun-27 4.5 P | 200 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Arbutus Biopharma Updates cHBV Programs and Clinical Data
TipRanks (Thu, 12-Nov 9:04 AM ET)
Arbutus Biopharma GAAP EPS of $0.30 beats by $0.32, revenue of $0.3M misses by $0.7M
Seeking Alpha News (Tue, 10-Nov 7:33 AM ET)
Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 10-Nov 7:30 AM ET)
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
Globe Newswire (Thu, 22-Oct 7:30 AM ET)
Arbutus Announces Final Results of Its US$230 Million Modified 'Dutch Auction' Tender Offer
Globe Newswire (Thu, 1-Oct 7:30 AM ET)
Market Chameleon (Wed, 30-Sep 7:39 AM ET)
Arbutus Announces Preliminary Results of Its US$230 Million Modified 'Dutch Auction' Tender Offer
Globe Newswire (Wed, 30-Sep 7:30 AM ET)
Globe Newswire (Mon, 24-Aug 7:30 AM ET)
Market Chameleon (Fri, 21-Aug 6:31 AM ET)
Market Chameleon (Fri, 21-Aug 3:48 AM ET)
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Arbutus Biopharma trades on the NASDAQ stock market under the symbol ABUS.
As of November 12, 2026, ABUS stock price climbed to $4.03 with 3,700,824 million shares trading.
ABUS has a beta of 1.22, meaning it tends to be more sensitive to market movements. ABUS has a correlation of 0.13 to the broad based SPY ETF.
ABUS has a market cap of $798.37 million. This is considered a Small Cap stock.
Last quarter Arbutus Biopharma reported $299,000 in Revenue and $.30 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.33.
In the last 3 years, ABUS traded as high as $5.45 and as low as $1.70.
The top ETF exchange traded funds that ABUS belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
ABUS has underperformed the market in the last year with a price return of -14.4% while the SPY ETF gained +12.0%. ABUS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.7% and -6.7%, respectively, while the SPY returned -1.5% and -2.0%, respectively.
ABUS support price is $3.76 and resistance is $4.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABUS shares will trade within this expected range on the day.
